Administrative Core

行政核心

• 批准号: 9187675
• 负责人: MAURO FERRARI
• 金额: $ 52.03万
• 依托单位: METHODIST HOSPITAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-08-29 至 2021-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9187675
• 关键词: Administrator; Advisory Committees; Biological; Budgets; Cancer Biology; Cancer Center; Cancer Immunology Science; Cancer Model; Cells; Clinical; Clinical Cancer Center; Communication; Communities; Computer Simulation; Consultations; Data; Dendritic Cell Vaccine; Direct Costs; Education and Outreach; Ensure; Evaluation; Faculty; Funding; Future; Goals; Image; Immune; Immune response; Immunotherapeutic agent; Institution; Intellectual Property; Leadership; Malignant Neoplasms; Malignant neoplasm of pancreas; Medical center; Methodist Church; National Cancer Institute; Nutrient; Pancreatic Ductal Adenocarcinoma; Patients; Performance; Pharmaceutical Preparations; Pilot Projects; Principal Investigator; Property; Research; Research Infrastructure; Research Institute; Research Personnel; Research Project Grants; Resource Sharing; Resources; Scientist; Students; T-Lymphocyte; Teacher Professional Development; Technology; Technology Transfer; Texas; Training and Education; Translations; United States National Institutes of Health; Universities; University of Texas M D Anderson Cancer Center; Vaccination; Wages; Work; cancer immunotherapy; conflict resolution; design; immunogenic; immunogenicity; improved; malignant breast neoplasm; meetings; member; oncology; physical property; physical science; programs; tumor microenvironment; tumor progression

ADMINISTRATIVE CORE – SUMMARY The proposed Center for Immunotherapeutic Transport Oncophysics (CITO) is focused on identifying and understanding the multi-scale transport properties of immune cells and molecules, both systemically and within the tumor microenvironment, and other specific biological and physical properties of the tumor microenvironment, to ultimately develop effective cancer immunotherapies. The major CITO components are summarized as follows. Project 1 proposes to determine the transport phenomena of dendritic cell (DC) vaccines for breast and pancreatic cancers and post-vaccination changes in the transport of endogenous DCs, effector T cells, and macromolecular drugs. This information will be used to improve immune responses in these two cancer models. Project 2 seeks to determine the effects of multi-scale transport phenomena of pancreatic ductal adenocarcinoma (PDAC) on the distribution of immune cells and nutrients in the tumor microenvironment, during tumor progression. The Transport Oncophysics Core (TOC) will support both projects with modeling, computational, and imaging capabilities to integrate the scientific data into parameters that ultimately inform the rational design of optimal cancer immunotherapeutics and to improve the immunogenicity of breast and pancreatic cancers, both of which are historically known to be lowly immunogenic. The Education and Outreach Unit (EOU) will serve as the communication and engagement platform for students, trainees, junior faculty investigators, and researchers of the CITO, and those of the Physical Sciences-Oncology Network (PS-ON) and beyond. The Administrative Core (AC) will be established as part of the CITO infrastructure through which the Principal Investigator (PI), Project Co-Leaders and Core Leader, researchers, trainees, advisors, NCI PS-ON program staff, and other scientific and patient communities can share information and synergize CITO-related activities. The AC will facilitate the accomplishment and evaluation of progress and the creation of a collaborative network for current and future scientists in physical sciences oncology. The AC will also oversee and manage the selection and funding of Pilot and Trans-Network Projects, coordinate the use of shared resources and facilities, and promote interaction with other PS-ON investigators. Dr. Mauro Ferrari (Center PI, senior physical sciences investigator, AC Co-Leader, TOC Leader; Houston Methodist Research Institute, HMRI) will serve as the AC Co-Leader (10% effort). Dr. Elizabeth Mittendorf (Center cancer clinical translation investigator; AC Co-Leader; Project 1 Co-Leader; MD Anderson Cancer Center), Dr. Rongfu Wang (Center senior cancer immunology investigator; AC Co-Leader; Project 1 Co-Leader; HMRI), and Dr. Rolf Brekken (senior cancer biology investigator; AC Co- Leader; Project 2 Co-Leader; UT Southwestern Medical Center) will also serve as the other three AC Co- Leaders (5% effort each in the AC). They will be supported by a Center Administrator and staff.

行政核心 - 摘要 免疫治疗运输肿瘤物质（CITO）的支撑性中心侧重于识别和 了解系统和 在肿瘤微环境以及肿瘤的其他特定生物学生物学和物理特性中 微环境，以实现有效的癌症免疫疗法。 总结如下。 乳腺癌和胰腺癌的疫苗以及内源性DC的运输后接种后的变化， 效应T细胞和大分子药物。 这两个癌症模型旨在确定多尺度运输现象的影响 胰腺导管腺癌（PDAC）在肿瘤中免疫细胞和养分的分布 微环境，在肿瘤进展过程中。 具有建模，计算和成像能力的项目，将科学数据集成到参数中 最终向最佳癌症免疫治疗剂的合理设计信息并改善了您 布雷斯特和胰腺癌的免疫原性，这两种都是历史悠久的 免疫原性。 学生，学员，初级教师调查员和CITO研究人员的平台以及您 物理科学 - 肿瘤网络（PS-ON）及以后。 作为CITO基础设施的一部分，主要研究员（PI），项目共同领导者和核心 负责人，研究人员，学员，顾问，NCI PS-ON计划人员以及其他科学和患者 社区可以共享信息，并协同CITO相关的活动。 进步的成就和评估以及为当前和未来创建协作网络 物理科学肿瘤学的科学家。 试点和跨网络项目，协调共享和设施的使用，并促进 与其他PS-investigators的互动。 TOC领导者AC共同领导人；休斯顿方法论家研究所，HMRI） （10％的努力） 共同领导者； MD Anderson癌症中心），Rongfu Wang博士（中央高级癌症免疫学研究者； AC共同领导者； 领导者；西南医疗中心的共同领导者 领导者（在AC中分别为5％）。